SNX-2112

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H27F3N4O3
Molecular Weight	464.4807
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)CC2=C(C(=NN2C3=CC=C(C(N)=O)C(N[C@H]4CC[C@H](O)CC4)=C3)C(F)(F)F)C(=O)C1

InChI

InChIKey=ZFVRYNYOPQZKDG-MQMHXKEQSA-N

InChI=1S/C23H27F3N4O3/c1-22(2)10-17-19(18(32)11-22)20(23(24,25)26)29-30(17)13-5-8-15(21(27)33)16(9-13)28-12-3-6-14(31)7-4-12/h5,8-9,12,14,28,31H,3-4,6-7,10-11H2,1-2H3,(H2,27,33)/t12-,14-

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18172276 | https://www.ncbi.nlm.nih.gov/pubmed/24582562 | https://www.ncbi.nlm.nih.gov/pubmed/25334086

SNX-2112, a novel 2-aminobenzamide inhibitor of heat shock protein 90 (Hsp90) was discovered by Serenex. This drug was investigated for treatment of different cancer cell lines, including hepatocellular carcinoma cells, breast cancer cells and in combination with 5-fluorouracil in esophageal cancer. However, subsequent development has been discontinued due to ocular toxicity as identified in a phase I study.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Heat shock protein HSP90 35 Target ID: CHEMBL2095165 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18172276	Inhibitor 8297		30.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Breast cancer 434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21821931	Primary	Basic research	Unknown Approved Use Unknown
Esophageal cancer 12 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25333998	Primary	Basic research	Unknown Approved Use Unknown
Hepatocellular carcinoma 83 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24582562	Primary	Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.	2009	20225761

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Treatment of BT-474 cells with 1 μM SNX-2112 results in down-regulation of HER2 expression. Treatment with SNX-2112 also results in a decline in total Akt expression. SNX-2112 inhibits cell proliferation with IC50 values ranging from 10 to 50 nM, in BT474, SKBR-3, SKOV-3, MDA-468, MCF-7 and H1650 cancer cells. And these antiproliferative effects are associated with hypophosphorylation of Rb, arrest of G1 and modest levels of apotosis.

Name

Type

Language

SNX-2112

Common Name

English

PF-04928473

Code

English

BENZAMIDE, 2-((TRANS-4-HYDROXYCYCLOHEXYL)AMINO)-4-(4,5,6,7-TETRAHYDRO-6,6-DIMETHYL-4-OXO-3-(TRIFLUOROMETHYL)-1H-INDAZOL-1-YL)-

Systematic Name

English

Code System Code Type Description

CAS

908112-43-6

Created by admin on Sat Dec 16 02:44:31 GMT 2023 , Edited by admin on Sat Dec 16 02:44:31 GMT 2023

PRIMARY

PUBCHEM

24772860

Created by admin on Sat Dec 16 02:44:31 GMT 2023 , Edited by admin on Sat Dec 16 02:44:31 GMT 2023

PRIMARY

FDA UNII

10C9P3FFOW

Created by admin on Sat Dec 16 02:44:31 GMT 2023 , Edited by admin on Sat Dec 16 02:44:31 GMT 2023

PRIMARY

EPA CompTox

DTXSID601025695

Created by admin on Sat Dec 16 02:44:31 GMT 2023 , Edited by admin on Sat Dec 16 02:44:31 GMT 2023

PRIMARY

ACTIVE MOIETY


					10C9P3FFOW

SNX-2112

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18172276 | https://www.ncbi.nlm.nih.gov/pubmed/24582562 | https://www.ncbi.nlm.nih.gov/pubmed/25334086

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

PubMed

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18172276 | https://www.ncbi.nlm.nih.gov/pubmed/24582562 | https://www.ncbi.nlm.nih.gov/pubmed/25334086